Amphastar Pharmaceuticals (AMPH) Competitors

Avidity Biosciences (NASDAQ:RNA) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, community ranking, analyst recommendations, profitability and dividends.

Which has preferable valuation & earnings, RNA or AMPH?

Amphastar Pharmaceuticals has higher revenue and earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$9.56M	189.54	-$212.22M	-$2.90	-7.84
Amphastar Pharmaceuticals	$644.40M	3.03	$137.54M	$2.58	15.51

Does the media refer more to RNA or AMPH?

In the previous week, Amphastar Pharmaceuticals had 7 more articles in the media than Avidity Biosciences. MarketBeat recorded 11 mentions for Amphastar Pharmaceuticals and 4 mentions for Avidity Biosciences. Amphastar Pharmaceuticals' average media sentiment score of 0.99 beat Avidity Biosciences' score of 0.94 indicating that Avidity Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amphastar Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is RNA or AMPH more profitable?

Amphastar Pharmaceuticals has a net margin of 21.34% compared to Amphastar Pharmaceuticals' net margin of -2,219.87%. Avidity Biosciences' return on equity of 26.95% beat Amphastar Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	-2,219.87%	-39.74%	-34.98%
Amphastar Pharmaceuticals	21.34%	26.95%	12.27%

Does the MarketBeat Community favor RNA or AMPH?

Amphastar Pharmaceuticals received 251 more outperform votes than Avidity Biosciences when rated by MarketBeat users. Likewise, 66.84% of users gave Amphastar Pharmaceuticals an outperform vote while only 64.11% of users gave Avidity Biosciences an outperform vote.

Company	Underperform	Outperform
Avidity Biosciences	Outperform Votes 134 64.11%	Underperform Votes 75 35.89%
Amphastar Pharmaceuticals	Outperform Votes 385 66.84%	Underperform Votes 191 33.16%

Do institutionals & insiders have more ownership in RNA or AMPH?

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 2.0% of Avidity Biosciences shares are held by company insiders. Comparatively, 28.4% of Amphastar Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Which has more volatility and risk, RNA or AMPH?

Avidity Biosciences has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.

Do analysts recommend RNA or AMPH?

Avidity Biosciences currently has a consensus target price of $36.33, indicating a potential upside of 59.85%. Amphastar Pharmaceuticals has a consensus target price of $66.00, indicating a potential upside of 64.96%. Given Avidity Biosciences' higher possible upside, analysts plainly believe Amphastar Pharmaceuticals is more favorable than Avidity Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Amphastar Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Amphastar Pharmaceuticals beats Avidity Biosciences on 14 of the 18 factors compared between the two stocks.